TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01037842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo three times a day added to metformin 500 mg three times a day for 16 weeks
Study: NCT04123925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
Study: NCT01075932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil
Description: Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil
Description: Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g placebo (olive oil) taken daily for 12 weeks
Study: NCT03705195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
Study: NCT04736264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual rehabilitation module: navigation and mobility
Description: The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual rehabilitation module: exercise
Description: An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual rehabilitation module: reading
Description: Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
Study: NCT01874951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 1 mg of naltrexone will be given twice daily to all patients assigned to active drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
Study: NCT00798551

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Risk counseling
Description: cardiovascular risk counseling regarding elevated blood pressure
Study: NCT01752348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin, US standard reference E.coli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin, US standard reference E.coli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin, US standard reference E.coli

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin, US standard reference E.coli
Study: NCT02308072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 35 mg/m\^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m\^2)
Study: NCT05915052

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-type suture ileostomy
Description: Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the traditional ileostomy
Description: Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
Study: NCT03092908

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mature vinegar
Description: Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (water)
Description: Administer 5 ml placebo (water) three times a day.
Study: NCT02308072

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
Study: NCT00555464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisolone given at 3 mg/kg/day by mouth for 12 week
Study: NCT02237612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02660281

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation 1200 cGy
Description: 1200 cGy TBI in 8 fractions

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation 1200 cGy
Description: 1200 cGy TBI in 8 fractions

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Pre-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given prior to the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pre-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given prior to the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pre-Stem Cell Infusion Mesna
Description: Mesna given prior to the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pre-Stem Cell Infusion Mesna
Description: Mesna given prior to the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Melphalan

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Melphalan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Description: Stem cell infusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Description: Stem cell infusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Description: Stem cell infusion
Study: NCT00687570

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fresubin Energy Drink
Description: Fresubin energy drink 30 kcal/kg\*dag-1, seven days before surgery

Intervention type: DRUG
Group type: OTHER
Intervention: Laxabon®
Description: Laxabon® 4 litres starting the day before surgery
Study: NCT02660281

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Description: Stem cell infusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Description: Stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given after the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given after the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given after the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given after the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given after the stem cell infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Mesna
Description: Mesna given after the Stem Cell Infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Mesna
Description: Mesna given after the Stem Cell Infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Mesna
Description: Mesna given after the Stem Cell Infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Mesna
Description: Mesna given after the Stem Cell Infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Mesna
Description: Mesna given after the Stem Cell Infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Thiotepa
Study: NCT01207570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endermotherapy
Description: The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive manual stretching
Description: The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
Study: NCT03127722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESSURE (BAY1454032)
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic tubal sterilization
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
Study: NCT01728519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT SC
Description: AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT ID
Description: AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo subcutaneous injections on days 1, 7, 14, 21 and 56

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ID
Description: Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
Study: NCT01972633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Endovenous Laser (1470nm) ablation of great or small saphenous vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Endovenous Laser (1470nm) ablation of great or small saphenous vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
Study: NCT00992667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin nebulization
Description: 6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
Study: NCT00508261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: Single dose intramuscular injection
Study: NCT00873418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training
Description: 16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping skills training
Description: 16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
Study: NCT01544998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: 10 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: 10 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline load
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline load
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
Study: NCT04577677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: tDCS and peripheral nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: tDCS and peripheral nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: tDCS and peripheral nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: tDCS and peripheral nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: tDCS and peripheral nerve stimulation
Study: NCT03056482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Ondansetron 8 MG prepared in a 100 mL normal saline min-bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.05mg/kg
Description: Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.1mg/kg
Description: Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
Study: NCT04440176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitidis group A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitidis group A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study: NCT03626779

Intervention type: OTHER
Group type: OTHER
Intervention: Prf
Description: Take 10cc blood from patient and gain prf blug
Study: NCT01103310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9392
Study: NCT03517553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS users in ESRD
Description: use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
Study: NCT05545982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video laryngoscope with Miller approach
Description: Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
Study: NCT02388503

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no added fruit extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruit extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruit extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruit extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruit extract
Study: NCT00598026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele- follow-up
Description: Remote transmission to the implantation centre every 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional follow-up
Description: Visits at the implantation centre every 3 months
Study: NCT01364870

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TENS
Description: High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
Study: NCT03554421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Description: A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
Study: NCT01349556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: tretinoin 0.025% cream
Study: NCT03742531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
Study: NCT01108900

Intervention type: DRUG
Intervention: sildenafil
Description: tables, 25,50,100 mg, on demand, 1 month